Investor Relations

2018 Press Releases

Keyword Search
 
Categories: 
All | Financial
Select Year:
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/06/18MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of CambridgePrinter Friendly Version
07/31/18MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UKPrinter Friendly Version
07/29/18MediciNova Announces Full Enrollment in ALS Biomarker Clinical TrialPrinter Friendly Version
07/09/18MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALSPrinter Friendly Version
06/19/18MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in JapanPrinter Friendly Version
05/09/18MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in GlioblastomaPrinter Friendly Version
05/08/18MediciNova to Present at the UBS Global Healthcare Conference in New YorkPrinter Friendly Version
05/07/18MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and WithdrawalPrinter Friendly Version
04/26/18MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual MeetingPrinter Friendly Version
04/24/18MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging DataPrinter Friendly Version
04/13/18MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, FrancePrinter Friendly Version
04/01/18MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim AnalysisPrinter Friendly Version
03/29/18MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine DependencePrinter Friendly Version
03/28/18MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral NeuropathyPrinter Friendly Version
03/12/18MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in TokyoPrinter Friendly Version
02/25/18MediciNova to Present at the Cowen Health Care Conference in BostonPrinter Friendly Version
02/18/18MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, CaliforniaPrinter Friendly Version
02/12/18MediciNova Announces Closing of Underwritten Public Offering of Common StockPrinter Friendly Version
02/07/18MediciNova Announces Pricing of Underwritten Public Offering of Common StockPrinter Friendly Version
02/07/18MediciNova Announces Proposed Underwritten Public Offering of Common StockPrinter Friendly Version
02/01/18MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease DrugPrinter Friendly Version
01/31/18MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San DiegoPrinter Friendly Version
01/30/18MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, CaliforniaPrinter Friendly Version
01/28/18MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, FrancePrinter Friendly Version
01/16/18MediciNova to Present at the 98th Annual Meeting of the Chemical Society of JapanPrinter Friendly Version